Ann: Positive new DMD Combination Therapy Data in mdx mice, page-25

And it’s not just Sarepta (3 drugs approved by FDA) working in this space. AVI Biopharma, Pepgen, Prosensa NS Pharma (one drug approved by FDA) and others are also working on exon skipping for DMD. Possible multiple licencing deals?.. “one article states “researchers hope that “cocktails” of antisense oligonucleotides that target multiple exons can be developed that might help a substantial portion of the DMD population”.. yet exon skipping only works for 13% of the patients. 1102 can also be used for inflammation to compliment these treatments and can be used on all DMD boys…and then there is Beckers..